A New Silk Road for Medicine: India and Uzbekistan Are Building a Rs. 90,000 Crore Pharma Gateway to Eurasia

Central Asia’s landlocked geography makes regional manufacturing hubs particularly valuable. For Indian firms, Uzbekistan offers a platform not just for exports but for deeper integration into Eurasian healthcare supply chains. If the initiative succeeds, Uzbekistan may become for pharmaceutical trade what Dubai became for logistics, that is, a gateway connecting regions.

The emerging India–Uzbekistan Health Trade Corridor may soon redraw the map of global pharmaceutical trade, opening a potential Rs. 90,000 crore gateway linking Indian medicine manufacturers with the rapidly expanding healthcare markets of Eurasia.

Its significance becomes clearer when viewed against the vulnerabilities of global supply chains. Nearly 20% of the world’s crude oil trade passes through the narrow waters of the Strait of Hormuz, and recurring tensions between Iran and the United States have repeatedly reminded policymakers how fragile strategic trade routes can be.

In an era when war in the Persian Gulf threatens the oil arteries that power the global economy, India may have quietly secured another strategic lifeline which carries medicines across the heart of Eurasia. The geography of medicine trade, it appears, is changing.

India’s Global Pharmacy Meets a Strategic Gap

India’s pharmaceutical industry has long been one of the pillars of its global economic influence. The sector is currently valued at around USD 50 billion, with exports contributing nearly USD 27 billion annually. Indian companies supply medicines to more than 200 countries, making the country one of the most geographically diversified pharmaceutical exporters in the world.

The scale of India’s contribution to global healthcare is remarkable, as nearly one out of every three tablets consumed globally is estimated to be manufactured in India. The country produces roughly 20% of global generic medicines and more than 60% of the world’s vaccines.

This influence became particularly visible during the Vaccine Maitri initiative, when India supplied COVID-19 vaccines to more than 90 countries across Asia, Africa, and Latin America. The programme demonstrated that healthcare supply chains can carry diplomatic weight as much as economic value.

Yet beneath this global success lies a structural imbalance. More than 55% of India’s pharmaceutical exports remain concentrated in highly regulated markets such as the United States and Europe. While these markets offer stability, overdependence also creates vulnerability when regulations, pricing pressures, or trade policies shift.

Diversifying export destinations has therefore become a strategic priority for India’s pharmaceutical sector. That search has increasingly turned toward the rising healthcare markets of Eurasia.

Why Eurasia’s Healthcare Market Matters

Behind the India–Uzbekistan corridor lies a powerful economic reality where Eurasia’s healthcare demand is expanding faster than its domestic production capacity.

Across Central Asia and the Commonwealth of Independent States (CIS), pharmaceutical imports have grown at more than 9% annually during the past decade. Rising incomes, ageing populations, and expanding healthcare infrastructure are all contributing to growing consumption of medicines, vitamins, botanical supplements, and functional nutrition products.

The dietary supplements market in the CIS alone already exceeds USD 5.8 billion annually, while the broader nutraceutical market across Eurasia is estimated between USD 7 billion and USD 10 billion.

At the same time, the region’s landlocked geography creates unique supply challenges. Central Asia sits far from major pharmaceutical manufacturing hubs, making logistics costs higher and delivery times longer. Regional manufacturing or distribution centres can therefore significantly reduce supply bottlenecks.

This gap between demand and domestic production presents a natural opening for India’s pharmaceutical industry.

Uzbekistan: The Strategic Crossroads of Eurasia

Few countries occupy a logistical position as strategically valuable as Uzbekistan’s. Located at the crossroads of Central Asia, the country connects major regional markets including Kazakhstan, Kyrgyzstan, Tajikistan, Russia, and parts of Eastern Europe. For companies seeking entry into Eurasian markets, Uzbekistan offers the possibility of reaching a population of more than 250 million people from a single regional base.

The domestic pharmaceutical market itself illustrates this opportunity. Uzbekistan’s drug market is estimated at roughly USD 1.8–2 billion, with imports accounting for more than 80% of total medicine consumption.

Recognising this dependency, the Uzbek government has launched an ambitious industrial strategy. It aims to increase domestic pharmaceutical production to 50% of national demand by 2030 while encouraging foreign investment in manufacturing, packaging, and formulation.

Today, the country hosts more than 20 specialised pharmaceutical manufacturing zones and industrial clusters designed to attract international companies. Over 9,000 pharmacies now operate across Uzbekistan, reflecting rapid expansion in organised retail healthcare networks.

Central Asia’s landlocked geography makes regional manufacturing hubs particularly valuable. For Indian firms, Uzbekistan offers a platform not just for exports but for deeper integration into Eurasian healthcare supply chains. If the initiative succeeds, Uzbekistan may become for pharmaceutical trade what Dubai became for logistics, that is, a gateway connecting regions.

Building the Indo–CIS Health Trade Corridor

The emerging corridor is not merely a bilateral trade agreement. It is being structured as a broader ecosystem that combines policy coordination, industry partnerships, and institutional trade platforms.

A key element of this framework is the collaboration between Uzbekistan’s Ministry of Health, Nutrify Today, and the Pharma Eurasia platform. Together, they are working to build a structured Indo–CIS pharmaceutical and nutraceutical trade corridor designed to simplify market entry for Indian companies.

The initiative focuses on several practical mechanisms. Regulatory harmonisation efforts aim to streamline product approvals and align compliance frameworks across Eurasian markets. Supply chain digitisation and documentation standardisation are also being promoted to reduce administrative complexity in cross-border trade.

Another emerging dimension is the use of AI-driven regulatory intelligence systems that help companies navigate evolving nutraceutical regulations across different countries. Such tools could significantly lower entry barriers for exporters seeking to operate across multiple markets simultaneously.

A Dual-City Trade Architecture

The corridor operates through a dual-city engagement model linking policy dialogue in India with commercial execution in Central Asia. In Mumbai, the Sumflex & C-Suite Summit hosted by Nutrify Today serves as a leadership forum where global CEOs, regulators, investors, and policymakers discuss innovation, compliance frameworks, and emerging healthcare markets.

Meanwhile, the commercial engine of the corridor will be Pharma Eurasia 2026, scheduled to take place in Tashkent from 20–22 May 2026. The exhibition is expected to bring together pharmaceutical manufacturers, ingredient suppliers, contract development and manufacturing organisations, regulators, distributors, and healthcare buyers from across Eurasia.

Events like these may appear as routine trade exhibitions, yet they often serve as the marketplaces where global supply chains quietly take shape.

Historical Roots Beneath Modern Trade

The idea of a health corridor between India and Central Asia is not entirely new. For over a millennium, the Silk Road connected Indian textiles, spices, and medicines with Central Asian and European markets.

Historical trade routes linking Samarkand and Bukhara with cities such as Delhi and Lahore facilitated not only the exchange of goods but also the spread of medical knowledge and healing traditions across regions. In many ways, the emerging corridor represents a modern revival of these historic connections, the only difference being that the caravans will now carry vaccines, nutraceuticals, and advanced pharmaceutical formulations.

India’s engagement with Central Asia has also gained renewed diplomatic momentum in recent years. The first India–Central Asia Summit in 2022 emphasised deeper cooperation in trade, connectivity, and healthcare, signalling a strategic shift in New Delhi’s regional engagement. Pharmaceutical collaboration fits naturally within this broader agenda.

A Corridor With Strategic Consequences

Behind the technical language of supply chains and trade platforms lies a larger story about economic diplomacy. India exports medicines to more than 200 countries, yet its next phase of growth will depend on building deeper partnerships with emerging markets. Corridors like the one developing with Uzbekistan reflect a new approach where trade is shaped not just by tariffs but by regulatory cooperation, technology platforms, and integrated supply networks.

Uzbekistan, for its part, is positioning itself as the bridge between South Asia and Eurasia’s healthcare markets. If these efforts succeed, the corridor could transform Tashkent into a major node linking India’s pharmaceutical industry with Central Asia and the CIS. It would create a new axis of healthcare trade stretching across the Eurasian landmass.

In an era when global supply chains often appear fragile and geopolitics can disrupt energy flows overnight, the subtle construction of a medicine corridor carries deeper significance. Because in the future of geopolitics, influence may not only travel through oil pipelines or shipping lanes but through boxes of life-saving medicines, crossing deserts and mountains, reconnecting regions once linked by the Silk Road, and shaping the health of millions.